摘要
Abstract
Objectives To evaluate the double pre-excitation syndrome ( CHAG) scheme for refractory recurrent acute myeloid leukemia ( ANLL ) and cannot tolerate high doses of chemotherapy in patients with efficacy, tolerability and adverse reac-tions.Methods Granulocyte colony stimulating factor [g-csf 100~200μg/(m2・ d), day 1~14 days, subcutaneous injection], Accra toxin (Acla 8~10mg/d, day 1~8days, intravenous), three pointed cedar ester alkali (1mg/(m2・ d), day 1~14days, in-travenous), to low-dose cytarabine [Ara-C, 8~10mg/(m2・ d), day 1~14days, every 12 hours subcutaneous injection], CHAG schemeinthetreatmentofrefractory,9casesofrecurrentANLL.Results 5cases(55.5%)patientsachievedcompleteremission (CR), 2 cases (22.2%) received partial response (PR), the total effective rate was 77.7%.Shown during chemotherapy adverse reactions such as bone marrow suppression, secondary infection and fever, no serious adverse reactions.Conclusions Double pre-excitation syndrome patients with refractory recurrent ANLL curative effect is good, adverse reaction, worth clinical promotion.关键词
双预激方案/难治/复发性/急性髓系白血病Key words
Double pre-excitation syndrome/Refractory and recurrent/Acute myeloid leukemia
